Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
Open Access
- 1 February 1995
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 48 (2) , 147-150
- https://doi.org/10.1136/jcp.48.2.147
Abstract
AIMS--To study the patterns of expression of topoisomerase II-alpha in primary invasive ductal breast carcinomas; to correlate this expression with clinicopathological data and prognosis. METHODS--Cryostat sections from 63 primary invasive ductal breast carcinomas were stained immunohistochemically for topoisomerase II-alpha. Nuclear immunoreactivity was quantified by counting at least 500 cells in different random fields and results were expressed as per cent of cells staining positively for topoisomerase II-alpha. RESULTS--Topoisomerase II-alpha nuclear immunoreactivity (median 14% of nuclei; range 2-62%) was detected in all tumours with highly variable intertumour and intratumour nuclear reactivity. Higher levels of topoisomerase II-alpha expression were strongly related to higher tumour grade, larger tumour size, nodal status, and the presence of distant metastases at diagnosis. No correlation was found with menopausal status, steroid hormone receptor status, disease free survival, or overall survival. CONCLUSIONS--Expression of topoisomerase II-alpha is related to the presence of poor prognostic factors. Immunohistochemical assessment of topoisomerase II-alpha expression in breast cancer could be potentially useful for tailoring chemotherapy with topoisomerase II inhibitors.Keywords
This publication has 25 references indexed in Scilit:
- Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20European Journal Of Cancer, 1993
- Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymesExperimental Cell Research, 1992
- The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnantExperimental Cell Research, 1992
- P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.1991
- Comparison of Monoclonal Immunocytochemical and Immunoenzymatic Methods for Steroid Receptor Evaluation in Breast CancerAmerican Journal of Clinical Pathology, 1991
- Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissuesBiochemistry, 1990
- Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes.Proceedings of the National Academy of Sciences, 1989
- Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase IIBiochemistry, 1989
- Oestrogen potentiates topoisomerase‐II‐mediated cytotoxicity in an activated subpopulation of human breast cancer cells: Implications for cytotoxic drug resistance in solid tumoursInternational Journal of Cancer, 1989
- Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22.Proceedings of the National Academy of Sciences, 1988